Drug Profile
Celecoxib/olmesartan - Adhera Therapeutics
Alternative Names: IT-103Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator IthenaPharma
- Developer Adhera Therapeutics
- Class Analgesics; Antihypertensives; Antirheumatics; Imidazoles; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
- Mechanism of Action Angiotensin type 1 receptor antagonists; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypertension
- Discontinued Arthritis; Cancer; Inflammation; Pain
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Hypertension in USA (PO, Tablet)
- 03 May 2019 Discontinued - Clinical-Phase-Unknown for Inflammation in USA (PO) (Adhera Therapeutics pipeline, May 2019)
- 03 May 2019 Discontinued - Preclinical for Arthritis in USA (PO) (Adhera Therapeutics pipeline, May 2019)